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Appendix 1: STROBE 2007 Statement 
 
Section/Topic Item 
# 
Recommendation 
Reported on 
page # 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title 
or the abstract 
Page 1 
(b) Provide in the abstract an informative and balanced summary of 
what was done and what was found 
Page 2 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation 
being reported 
Page 3-4 
Objectives 3 State specific objectives, including any prespecified hypotheses Page 3-4 
Methods  
Study design 4 Present key elements of study design early in the paper Study Design and 
Participants  
 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
Study Design and 
Participants  
 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of 
selection of participants. Describe methods of follow-up 
Study Design and 
Participants  
 
(b) For matched studies, give matching criteria and number of exposed 
and unexposed 
Not applicable 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if 
applicable 
Risk Factor 
Assessment 
 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe comparability of 
assessment methods if there is more than one group 
Risk Factor 
Assessment 
 
Bias 9 Describe any efforts to address potential sources of bias Statistical 
Analyses 
 
Study size 10 Explain how the study size was arrived at Statistical 
Analyses 
 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why 
Statistical 
Analyses 
 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for 
confounding 
Statistical 
Analyses 
 
(b) Describe any methods used to examine subgroups and interactions Statistical 
Analyses 
 
(c) Explain how missing data were addressed Not applicable 
(d) If applicable, explain how loss to follow-up was addressed Not applicable 
  
(e) Describe any sensitivity analyses Statistical 
Analyses 
 
Results  
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, 
included in the study, completing follow-up, and analysed 
Study population 
  (b) Give reasons for non-participation at each stage Study population 
  (c) Consider use of a flow diagram  
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, 
clinical, social) and information on exposures and potential 
confounders 
Results; Table 1; 
Appendix 2  
  (b) Indicate number of participants with missing data for each variable 
of interest 
 
  (c) Summarise follow-up time (eg, average and total amount) Results 
Outcome data 15* Report numbers of outcome events or summary measures over time Results 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make 
clear which confounders were adjusted for and why they were 
included 
Results; Tables 2-
4 
  (b) Report category boundaries when continuous variables were 
categorized 
Results; Tables 2-
4 
  (c) If relevant, consider translating estimates of relative risk into 
absolute risk for a meaningful time period 
 
Other analyses 17 Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses 
Results; Figure 2 
Discussion    
Key results 18 Summarise key results with reference to study objectives Discussion - 
Summary of main 
findings 
Limitations    
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and 
other relevant evidence 
Discussion 
Generalisability 21 Discuss the generalisability (external validity) of the study results Discussion 
Other information    
Funding 22 Give the source of funding and the role of the funders for the present 
study and, if applicable, for the original study on which the present 
article is based 
Page 16 
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Appendix 2. Baseline participant characteristics by quartiles of serum magnesium 
 Quartile 1 
Mean (SD), 
median (IQR), 
or n (%) 
Quartile 2 
Mean (SD), 
median (IQR), 
or n (%)) 
Quartile 3 
Mean (SD), 
median (IQR), 
or n (%) 
Quartile 4 
Mean (SD), 
median (IQR), 
or n (%) 
P-value 
Magnesium (mg/dl) 1.79 (0.09) 1.93 (0.03) 2.03 (0.3) 2.17 (0.08) < 0.0001 
      
Questionnaire/Prevalent conditions      
Age at survey (years) 53.1 (5.5) 52.4 (5.7) 53.3 (4.8) 53.7 (3.9) 0.0002 
Alcohol consumption (g/week) 86.8 (170.8) 78.9 (154.8) 71.6 (101.1) 66.0 (110.3) 0.063 
Total energy intake, kJ/day 9,998 (2,736) 9,900 (2,676) 9,871 (2,557) 9,647 (2,450) 0.143 
Socioeconomic status 8.70 (4.09) 8.46 (4.24) 8.60 (4.30) 8.26 (4.33) 0.339 
Dietary magnesium intake (mg/day) 419.4 (72.2) 419.6 (69.7) 417.2 (64.3) 412.3 (70.8) 0.266 
History of diabetes      
    No 527 (93.1) 534 (95.7) 551 (97.7) 544 (97.7)  
    Yes 39 (6.9) 24 (4.3) 13 (2.3) 13 (2.3) < 0.001 
Smoking status      
    Other 384 (67.8) 389 (69.7) 374 (66.3) 382 (68.6)  
    Current 182 (32.2) 169 (30.3) 190 (33.7) 175 (31.4) 0.665 
History of hypertension      
    No 387 (68.4) 387 (69.4) 394 (69.9) 396 (71.1)  
    Yes 179 (31.6) 171 (30.7) 170 (30.1) 161 (28.9) 0.796 
      
Physical measurements      
BMI (kg/m2) 27.2 (3.8) 26.7 (3.5) 27.0 (3.5) 26.9 (3.5) 0.209 
Height (cm) 173.0 (6.1) 172.9 (6.3) 172.9 (6.3) 172.5 (6.2) 0.560 
SBP (mmHg) 134 (17) 134 (16) 134 (17) 134 (18) 0.931 
DBP (mmHg) 89 (11) 88 (10) 89 (10) 88 (11) 0.513 
Physical activity (kj/day) 1,500 (1,414) 1,596 (1,658) 1,547 (1,370) 1,540 (1,502) 0.760 
      
Lipid markers      
Total cholesterol (mmol/l) 5.82 (1.13) 5.82 (1.10) 5.93 (1.02) 6.06 (1.05) 0.0002 
HDL-C (mmol/l) 1.31 (0.33) 1.29 (0.29) 1.29 (0.28) 1.28 (0.29) 0.485 
Triglycerides (mmol/l) 1.08 (0.79-1.53) 1.08 (0.79-1.52) 1.11 (0.80-1.57) 1.12 (0.83-1.64) 0.118 
      
Metabolic and renal markers      
Fasting plasma glucose (mmol/l) 5.73 (1.96) 5.25 (0.96) 5.24 (0.79) 5.22 (0.94) < 0.0001 
Serum creatinine (µmol/1) 87.2 (15.3) 89.1 (14.3) 89.9 (12.5) 92.7 (34.8) 0.0002 
Estimated GFR (ml/min/1.73 m2) 90.1 (17.7) 87.7 (15.7) 86.1 (19.0) 84.0 (15.7) < 0.0001 
      
Trace elements      
Serum zinc (mg/l) 0.92 (0.13) 0.94 (0.12) 0.94 (0.11) 0.95 (0.12) 0.0006 
Serum ionized calcium (mmol/l) 1.18 (0.05) 1.18 (0.05) 1.18 (0.05) 1.18 (0.05) 0.016 
Serum potassium (mmol/l) 3.93 (0.28) 3.93 (0.37) 3.92 (0.27) 3.90 (0.29) 0.171 
 
BMI, body mass index; CHD, coronary heart disease; CI, confidence interval; DBP, diastolic blood pressure; GFR, glomerular filtration rate;  
HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; SD, standard deviation; SBP, systolic blood pressure;  
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Appendix 3. Hazard ratios for incident femoral fractures by quartiles of serum magnesium levels 
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A, adjusted for age; B, adjusted for age, body mass index, height, systolic blood pressure, smoking status, 
history of diabetes, alcohol consumption, and physical activity; the mean magnesium level (mg/dl) was 1.79 
for the lowest quartile; 1.93 for the second quartile; 2.03 for the third quartile; and 2.17 for the top quartile; 
CI, confidence interval 
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Appendix 4. Association of serum magnesium and incident fractures by quartiles of serum magnesium (with 
quartile 1 as reference comparison) 
Serum 
magnesium(mg/dl) 
Events/ 
Total 
Model 1  Model 2  Model 3  
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Total fractures 
Q1 (0.92-1.88) 46 / 566 ref  ref  ref  
Q2 (1.88-1.98) 27 / 558 0.53 (0.33 to 0.86) 0.010 0.55 (0.34 to 0.89) 0.015 0.56 (0.35 to 0.91) 0.019 
Q3 (1.98-2.08) 24 / 564 0.44 (0.27 to 0.72) 0.001 0.46 (0.28 to 0.76) 0.002 0.48 (0.29 to 0.79) 0.004 
Q4 (2.08-2.55) 26 / 557 0.48 (0.29 to 0.77) 0.003 0.50 (0.31 to 0.82) 0.005 0.56 (0.34 to 0.91) 0.019 
Femoral fractures 
Q1 (0.92-1.88) 31 / 559 ref  ref  ref  
Q2 (1.88-1.98) 16 / 553 0.47 (0.26 to 0.86) 0.014 0.49 (0.27 to 0.90) 0.022 0.51 (0.27 to 0.94) 0.031 
Q3 (1.98-2.08) 16 / 556 0.42 (0.23 to 0.77) 0.005 0.44 (0.24 to 0.81) 0.009 0.47 (0.26 to 0.87) 0.017 
Q4 (2.08-2.55) 15 / 556 0.39 (0.21 to 0.73) 0.003 0.41 (0.22 to 0.77) 0.005 0.47 (0.25 to 0.88) 0.019 
 
CI, confidence interval; HR, hazard ratio; ref, reference; Q, quartile 
Model 1: Adjusted for age  
Model 2: Model 1 plus body mass index, height, systolic blood pressure, smoking, history of diabetes, alcohol consumption, and 
physical activity 
Model 3: Model 2 plus estimated glomerular filtration rate, socioeconomic status, total energy intake, serum zinc, serum potassium, 
and serum ionized calcium 
 
 
